About Therakos
Therakos is a Healthcare company based in West Chester (United States) founded in 1984, and was acquired by CVC in August 2024. Therakos is focused on photopheresis systems for CTCL treatment. It operates on a HealthTech and Direct-to-Consumer (D2C) model. Therakos offers products and services including THERAKOS CELLEX Photopheresis System and UVADEX (methoxsalen) Sterile Solution. Its focus areas include Medical Devices, Photopheresis Systems, Pharmaceuticals and Dermatological Treatments. Its legal entity is Therakos LLC. Its competitors include SetPoint Medical, Aura Biosciences and Boomerang Medical; 3 of its 3 listed competitors have raised funding.
Company details
Therakos is engaged in providing photopheresis solutions for the palliative treatment of cutaneous T-cell lymphoma (CTCL) skin manifestations. The company offers the THERAKOS CELLEX Photopheresis System and UVADEX (methoxsalen) Sterile Solution, targeting healthcare professionals in the United States. Services are extended through customer support, professional resources, and the Therakos Institute to build a community of expert operators. The focus is placed on the healthcare sector, specifically in dermatological and oncological treatment solutions.
- Headquarters West Chester, United States
- Stage Acquired
- SectorsHealthcare
- Website therakos.com
- Social LinkedIn Facebook YouTube
- Acquired by Mallinckrodt Pharmaceuticals (Aug 2015)
- Legal Name Therakos Llc
Products & Services of Therakos
Therakos offers a comprehensive portfolio of products and services, including THERAKOS CELLEX Photopheresis System and UVADEX (methoxsalen) Sterile Solution.
Used for palliative treatment of CTCL skin manifestations.
Administered extracorporeally for CTCL skin symptom treatment.
Apps and channels of Therakos
its YouTube channel Therakos Inc. has 331 subscribers and 7 videos.
Videos from Therakos
The most watched videos on Therakos's YouTube channel, Therakos Inc. (331 subscribers). Click a video to play it here.
More on Therakos Inc..
Investors in Therakos
Therakos has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include CVC, Mallinckrodt Pharmaceuticals and The Gores Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Mezzanine financing and equity investments are provided by CVC. | 1981 | cvc.com | New York, United States | |
Private investments are made in mature businesses across multiple sectors. | 1987 | gores.com | Los Angeles, United States | |
Specialty pharmaceutical products and diagnostic imaging agents are manufactured. | 1867 | mallinckrodt.com | St. Louis, United States |
Investor details for Therakos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Therakos
4 dated milestones of Therakos across 40 years, from founding to its latest funding, stage changes and deals.
- Founded Therakos is founded.
- Exit Acquired by The Gores Group.
- Exit Acquired by Mallinckrodt Pharmaceuticals.
- Exit Acquired by CVC.
Competitors of Therakos
Therakos has 3 listed competitors in our database, 3 of them funded. They include SetPoint Medical, Aura Biosciences and Boomerang Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| setpointmedical.com | 2006 | Santa Clarita, United States | $363.17M | 46 | Implantable neuromodulation devices are developed for inflammatory diseases. | |
| aurabiosciences.com | 2007 | Cambridge, United States | $215.46M | 21 | Therapies are developed to target and destroy cancer cells selectively. | |
| boomerangmedical.com | 2021 | Mountain View, United States | $35M | Bioelectronic devices are developed for autoimmune disease treatment. |
Detailed competitors of Therakos
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Therakos
The website of Therakos (therakos.com) receives about 6.2K visits a month.
- Monthly visits6.2K
▼ 21.5% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Therakos (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Therakos
Complete news archive for Therakos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Therakos
Therakos was founded in 1984.
Therakos is headquartered in West Chester, United States. It is registered at West Chester, Pennsylvania, United States.
Therakos is engaged in providing photopheresis solutions for the palliative treatment of cutaneous T-cell lymphoma (CTCL) skin manifestations. The company offers the THERAKOS CELLEX Photopheresis System and UVADEX (methoxsalen) Sterile Solution, targeting healthcare professionals in the United States. Services are extended through customer support, professional resources, and the Therakos Institute to build a community of expert operators. The focus is placed on the healthcare sector, specifically in dermatological and oncological treatment solutions.
Therakos's top competitors include SetPoint Medical, Aura Biosciences and Boomerang Medical.
Therakos offers THERAKOS CELLEX Photopheresis System and UVADEX (methoxsalen) Sterile Solution.
Therakos has 3 investors. Key investors include CVC, Mallinckrodt Pharmaceuticals, and The Gores Group.
Therakos operates through Therakos Llc.
Yes. Therakos was acquired by Mallinckrodt Pharmaceuticals in August 2015.